» Authors » Filippo Testa

Filippo Testa

Explore the profile of Filippo Testa including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 24
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Marino G, Marchetta L, Negri S, Testa F, Lugotti D, Cavallo G, et al.
Gynecol Oncol . 2024 Nov; 192():89-93. PMID: 39561630
Background: Granulosa cell tumors (GCTs) are rare neoplasia that account for less than 5 % of all the ovarian tumors. Juvenile GCT histotype is generally observed in adolescent and young...
2.
Marino G, Grassi T, De Ponti E, Testa F, Negri S, Giuliani D, et al.
Int J Gynecol Cancer . 2024 Sep; 34(9):1416-1422. PMID: 39222973
Objective: To evaluate the impact of adjuvant chemotherapy, type of ovarian surgery, and the surgical approach on fertility in patients with stage I immature teratoma of the ovary. Methods: Clinicopathologic...
3.
Bianchi T, Grassi T, Bazzurini L, Testa F, Corti J, Pecis Cavagna G, et al.
Eur J Surg Oncol . 2024 Jul; 50(9):108523. PMID: 38996586
Objective: The standard surgical treatment of advanced ovarian carcinoma is primary debulking surgery (PDS) aiming to complete cytoreduction. The need to achieve complete cytoreduction has shifted the surgical paradigm to...
4.
Tomaino G, Pantaleoni C, DUrzo A, Santambrogio C, Testa F, Ciprandi M, et al.
Int J Mol Sci . 2024 Jun; 25(12). PMID: 38928334
Vaults are eukaryotic ribonucleoproteins consisting of 78 copies of the major vault protein (MVP), which assemble into a nanoparticle with an about 60 nm volume-based size, enclosing other proteins and...
5.
Marino G, Grassi T, De Ponti E, Negri S, Testa F, Giuliani D, et al.
Front Oncol . 2024 Feb; 14:1330481. PMID: 38371620
Objective: Immature teratomas are rare malignant ovarian germ cell tumours, typically diagnosed in young women, where fertility-sparing surgery is the treatment of choice. The role of adjuvant chemotherapy in stage...
6.
Colombo E, Coppini D, Maculan S, Seneci P, Santini B, Testa F, et al.
RSC Adv . 2022 Dec; 12(54):35484-35493. PMID: 36544466
Hetero-nanoparticles self-assembled from a conjugate bearing folic acid as the targeting agent, and another bearing paclitaxel as the active agent are reported. Hetero-nanoparticles containing varying percentages of folic acid conjugates...
7.
Salvioni L, Testa F, Sulejmani A, Pepe F, Lovaglio P, Berta P, et al.
Clin Chim Acta . 2022 Nov; 537:140-145. PMID: 36341812
Background: Surfactant protein-D (SP-D) is a lung-resident protein that has emerged as a potential biomarker for COVID-19. Previous investigations on acute respiratory distress syndrome patients demonstrated a significant increment of...
8.
Massironi N, Colombo M, Cosentino C, Fiandra L, Mauri M, Kayal Y, et al.
Molecules . 2022 Oct; 27(20). PMID: 36296711
In this study, superparamagnetic iron oxide nanoparticles (SPIONs) were engineered with an organic coating composed of low molecular weight heparin (LMWH) and bovine serum albumin (BSA), providing heparin-based nanoparticle systems...
9.
Salvioni L, Testa F, Barbieri L, Giustra M, Bertolini J, Tomaino G, et al.
Pharmaceutics . 2022 Jul; 14(7). PMID: 35890411
Ribosome-inactivating proteins, including Saporin toxin, have found application in the search for innovative alternative cancer therapies to conventional chemo- and radiotherapy. Saporin's main mechanism of action involves the inhibition of...
10.
Tullio C, Salvioni L, Bellini M, Degrassi A, Fiandra L, DArienzo M, et al.
ACS Appl Bio Mater . 2021 Nov; 4(11):7800-7810. PMID: 34805780
Magnetic resonance imaging (MRI) is one of the most sophisticated diagnostic tools that is routinely used in clinical practice. Contrast agents (CAs) are commonly exploited to afford much clearer images...